Redalpine

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.

Daedalean AG, founded in 2016 and based in Zurich, Switzerland, specializes in developing autonomous flight control systems for electric personal aircraft. The company focuses on creating machine-learning-based avionics systems for both current civil aviation and future advanced aerial mobility. With a team exceeding 150 professionals, including experts in machine learning and aviation, Daedalean is working on certification and market introduction of its AI-driven products, such as Pilot Eye™ and Ailumina Vista™, designed for visual traffic detection in fixed-wing aircraft and helicopters. Additionally, the company offers solutions for non-GNSS positioning, landing guidance, and power line detection. Daedalean has established collaborations with aviation regulators and has produced joint reports with entities like EASA and the FAA, facilitating the certification process for its innovative, safety-critical aviation applications.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.

Versantis AG is a Swiss pharmaceutical company focused on developing innovative medicines and diagnostics for liver diseases. Founded in 2015 and based in Zurich, the company is dedicated to addressing the unmet medical needs of patients globally. Its lead candidate, VS-01, is in the preclinical stage and aims to be the first drug for acute liver disease, with the unique capability of supporting multiple organ function. VS-01 has received Orphan Drug Designation for acute liver failure, highlighting its potential in treating rare conditions. Additionally, Versantis is advancing other products in its pipeline, including VS-02 and VS-03, which target chronic liver diseases and drug intoxications, respectively. These developments represent significant opportunities for improving patient outcomes in the field of liver health and beyond.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.

Daedalean AG, founded in 2016 and based in Zurich, Switzerland, specializes in developing autonomous flight control systems for electric personal aircraft. The company focuses on creating machine-learning-based avionics systems for both current civil aviation and future advanced aerial mobility. With a team exceeding 150 professionals, including experts in machine learning and aviation, Daedalean is working on certification and market introduction of its AI-driven products, such as Pilot Eye™ and Ailumina Vista™, designed for visual traffic detection in fixed-wing aircraft and helicopters. Additionally, the company offers solutions for non-GNSS positioning, landing guidance, and power line detection. Daedalean has established collaborations with aviation regulators and has produced joint reports with entities like EASA and the FAA, facilitating the certification process for its innovative, safety-critical aviation applications.

RosieReality, founded in 2017 and based in Zurich, Switzerland, develops an educational mobile application named Rosie, aimed at children aged 9 and up. The app utilizes augmented reality to engage kids in learning about science and basic robotics coding through interactive challenges. Users program Rosie the Robot by manipulating magical 3D shapes to solve AR puzzles, making the learning experience both fun and educational. The application is designed to foster curiosity and interest in scientific exploration, providing parents with a valuable tool for enriching their children's early education.

Versantis AG is a Swiss pharmaceutical company focused on developing innovative medicines and diagnostics for liver diseases. Founded in 2015 and based in Zurich, the company is dedicated to addressing the unmet medical needs of patients globally. Its lead candidate, VS-01, is in the preclinical stage and aims to be the first drug for acute liver disease, with the unique capability of supporting multiple organ function. VS-01 has received Orphan Drug Designation for acute liver failure, highlighting its potential in treating rare conditions. Additionally, Versantis is advancing other products in its pipeline, including VS-02 and VS-03, which target chronic liver diseases and drug intoxications, respectively. These developments represent significant opportunities for improving patient outcomes in the field of liver health and beyond.

Bexio AG is a Swiss company that specializes in providing cloud-based business and accounting software tailored for small and medium-sized enterprises. Founded in 2013 and based in Rapperswil, the company was previously known as easySYS AG before rebranding in 2015. Bexio AG focuses on simplifying accounting processes and enhancing business management through its user-friendly platform, which employs a standardized interface to facilitate interactions between businesses and their trustees, banks, and service providers. As of mid-2018, Bexio operates as a subsidiary of Schweizerische Mobiliar Versicherungsgesellschaft AG, reflecting its commitment to supporting the growth and efficiency of small businesses in Switzerland.

Knip AG, founded in September 2013 by Dennis Just and Christina Kehl, operates as an innovative insurance management company with offices in Zurich, Berlin, and Belgrade. The firm has grown significantly, employing over 100 staff members and receiving funding from venture capitalists across the U.S., Switzerland, Germany, and the Netherlands. Knip's primary offering is its mobile application, which allows users to manage all their insurance policies, premiums, and benefits in one place. The app facilitates tasks such as adjusting premiums, executing new policies, and canceling existing ones. Additionally, Knip provides users with biannual financial reviews to help them identify suitable tariffs and products. With a focus on transparency and unbiased advice, the company's insurance experts are available to assist users in navigating their insurance needs effectively. Knip is registered with the German Chamber of Industry & Commerce and certified by the German Technical Inspection Agency.

Bexio AG is a Swiss company that specializes in providing cloud-based business and accounting software tailored for small and medium-sized enterprises. Founded in 2013 and based in Rapperswil, the company was previously known as easySYS AG before rebranding in 2015. Bexio AG focuses on simplifying accounting processes and enhancing business management through its user-friendly platform, which employs a standardized interface to facilitate interactions between businesses and their trustees, banks, and service providers. As of mid-2018, Bexio operates as a subsidiary of Schweizerische Mobiliar Versicherungsgesellschaft AG, reflecting its commitment to supporting the growth and efficiency of small businesses in Switzerland.

Redbiotec is a private biotechnology company based in Zurich-Schlieren, founded in 2006 as a spin-off from ETH Zürich. The company has a history of innovation in vaccine development, having sold its cytomegalovirus (CMV) vaccine business to Pfizer in 2015 and developed an immunotherapy for herpes simplex virus type 2 (HSV-2). Currently, Redbiotec focuses on creating bacteria-based gene therapies aimed at treating cancer and genetic disorders. Utilizing a proprietary platform, the company is capable of accommodating large and diverse therapeutic cargos, effectively addressing delivery challenges that hinder other therapeutic vehicles. Redbiotec's approach includes the development of prophylactic vaccines that leverage virus-like particles targeting various viral infections, thereby contributing to unmet medical needs in the healthcare sector.

Knip AG, founded in September 2013 by Dennis Just and Christina Kehl, operates as an innovative insurance management company with offices in Zurich, Berlin, and Belgrade. The firm has grown significantly, employing over 100 staff members and receiving funding from venture capitalists across the U.S., Switzerland, Germany, and the Netherlands. Knip's primary offering is its mobile application, which allows users to manage all their insurance policies, premiums, and benefits in one place. The app facilitates tasks such as adjusting premiums, executing new policies, and canceling existing ones. Additionally, Knip provides users with biannual financial reviews to help them identify suitable tariffs and products. With a focus on transparency and unbiased advice, the company's insurance experts are available to assist users in navigating their insurance needs effectively. Knip is registered with the German Chamber of Industry & Commerce and certified by the German Technical Inspection Agency.

Redvax is a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. Redvax is a preclinical stage company. The company develops multi-component virus-like particles (VLPs) and other protein assemblies for vaccine development in the field of CMV and a further undisclosed field.